HFE gene mutations in coronary atherothrombotic disease

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 3, 2000, Pages 301-306

  Calado, R T ^a,b   Franco, R F ^a   Pazin Filho, A ^a   Simoes M V ^a   Marin Neto, J A ^a   Zago, M A ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fundacao Hemocentro de Ribeirao Preto   (Brazil)

Author keywords

Atherosclerosis; Hemochromatosis; HFE gene; Myocardial infarction; Risk factor

Indexed keywords

HFE PROTEIN, HUMAN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ADULT; ALLELE; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GENE; GENE FREQUENCY; GENETICS; HEMOCHROMATOSIS; HUMAN; MALE; MIDDLE AGED; MUTATION;

ADULT; ALLELES; CORONARY ARTERIOSCLEROSIS; FEMALE; GENE FREQUENCY; GENES, MHC CLASS I; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION;

EID: 0034146770     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000300007     Document Type: Article

References (30)

1. Sullivan JL (1981). Iron and the sex difference in the heart disease risk. Lancet, 307: 1293-1294.
2. McCord JM (1998). Iron, free radicals, and oxidative injury. Seminars in Hematology, 35: 5-12.
3. Corti MC, Gaziano M & Hennekens CH (1997). Iron status and risk of cardiovascular disease. Annals of Epidemiology, 7: 62-68.
4. Meyers DG (1996). The iron hypothesis -does iron cause atherosclerosis? Clinical Cardiology, 19: 925-929.
5. Diaz MN, Frei B, Vita JA & Keaney Jr JF (1997). Antioxidants and atherosclerotic heart disease. New England Journal of Medicine, 337: 408-417.
6. Araújo JA, Romano EL, Brito BE, Parthe V, Romano M, Bracho M, Montano RF & Cardier J (1995). Iron overload augments the development of atherosclerotic lesions in rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 15: 1172-1180.
7. Dabbagh AJ, Shwaery GT, Keaney Jr JF & Frei B (1997). Effect of iron overload aid iron deficiency on atherosclerosis in the hypercholesterolemic rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 17: 2638-2645.
8. Lauffer RB (1990). Iron stores and the international variation in the mortality from coronary artery disease. Medical Hypotheses, 35: 96-102.
9. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R & Salonen R (1992). High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation, 86: 803-811.
10. Morrison HI, Semenciw RM, Mao Y & Wigle DT (1994). Serum iron and risk of fatal acute myocardial infarction. Epidemiology, 5: 243-246.
11. Kiechl S, Willeit J, Egger G, Poewe W & Oberhollenzer F (1997). Body iron stores and the risk of carotid atherosclerosis. Circulation, 96: 3300-3307.
12. Sempos CT, Looker AC, Gillium RF & Maruk DM (1994). Body iron stores and the risk of coronary heart disease. New England Journal of Medicine, 330: 1119-1124.
13. Stampfer MJ, Grodstein F, Rosemberg I, Willett W & Hennekens C (1993). A prospective study of plasma ferritin and risk of myocardial infarction in US physicians. Circulation, 87: 688 (Abstract).
14. Reunanen A, Takkunen H, Knekt P, Seppänen R & Aromaa A (1995). Body iron states, dietary iron intake and coronary heart disease mortality. Journal of Internal Medicine, 238: 223-230.
15. Bothwell TH & MacPhail P (1998). Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Seminars in Hematology, 35: 55-71.
16. Andrews NC & Levy JE (1998). Iron ts hot: an update on the pathophysiology of hemochromatosis. Blood, 92: 1845-1851.
17. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo Jr R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KN, Drayna DT, Risch NJ, Bacon BR & Wolff RK (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13: 399-407.
18. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, Kosty M, Venditti CP, Phatak PD, Seese NK, Chorney KA, Ten Elshof AE, Gerhard GS & Chorney M (1996). Mutation analysis in hereditary hemochromatosis. Blood Cells, Molecules, and Diseases, 22: 187-194.
19. Garry PJ, Montoya GD, Baumgartner RN, Liang HC, Williams TM & Brodie SG (1997). Impact of HLA-H mutations on iron stores in healthy elderly men and women. Blood Cells, Molecules, and Diseases, 23: 277-287.
20. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higushi R, Horn GT, Mubis KB & Erlich HA (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239: 487-491.
21. Merryweather-Clarke AT, Pointon JJ, Shearman JD & Robson KJH (1997). Global prevalence of putative haemochromatosis mutations. Journal of Medical Genetics, 34: 275-278.
22. Woolf B (1955). On estimating the relation between blood group and disease. American Journal of Human Genetics, 19: 251.
23. Gillum RF (1997). Body iron stores and atherosclerosis. Circulation, 96: 3261-3263.
24. Burt MJ, Halliday JW & Powell LW (1993). Iron and coronary heart disease. British Medical Journal, 307: 575-576.
25. Ascherio A & Willett WC (1994). Are body iron stores related to the risk of coronary heart disease? New England Journal of Medicine, 330: 1152-1153.
26. Annichino-Bizzachi JM, Saad STO, Arruda VR, Siqueira LH, Chiaparini LC & Mansur AP (1997). Mutação CYS282TYR relacionada à hemocromatose em pacientes com intarto do miocárdio. Anais do XVI Congresso Nacional do Colégio Brasileiro de Hematologia, Belo Horizonte, P148 (Abstract).
27. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE & Hennekens CH (1991). Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. New England Journal of Medicine, 325: 756-762.
28. Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS & Vercellotti GM (1995). Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. American Journal of Pathology, 147: 782-789.
29. Franco RF, Zago MA, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJP & Reitsma PH (1998). Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. British Journal of Haematology, 102: 1172-1175.
30. Jeffrey GP, Chakrabarti S, Hegele RA & Adams PC (1999). Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nature Genetics, 22: 325-326.